Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
US Department of Justice
Moodys
Deloitte
Express Scripts
Novartis
Cipla
Johnson and Johnson
Cerilliant
Healthtrust

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 9,402,805

« Back to Dashboard

Which drugs does patent 9,402,805 protect, and when does it expire?

Patent 9,402,805 protects CIPRODEX and is included in one NDA.

This patent has eighteen patent family members in sixteen countries.
Summary for Patent: 9,402,805
Title:Method of treating middle ear infections
Abstract: Aqueous suspension formulations containing dexamethasone and ciprofloxacin are disclosed for the treatment of middle ear infections in human patients having an open tympanic membrane.
Inventor(s): Wall; G. Michael (Fort Worth, TX), Conroy; Peter J. (Fort Worth, TX)
Assignee: Alcon Pharmaceuticals Ltd. (Fribourg, CH)
Application Number:15/142,225
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation;

Drugs Protected by US Patent 9,402,805

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novartis Pharms Corp CIPRODEX ciprofloxacin; dexamethasone SUSPENSION/DROPS;OTIC 021537-001 Jul 18, 2003 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF ACUTE OTITIS MEDIA ➤ Sign Up
Novartis Pharms Corp CIPRODEX ciprofloxacin; dexamethasone SUSPENSION/DROPS;OTIC 021537-001 Jul 18, 2003 RX Yes Yes ➤ Sign Up ➤ Sign Up Y TREATMENT OF ACUTE OTITIS EXTERNA ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 9,402,805

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,846,650 Method of treating middle ear infections ➤ Sign Up
9,149,486 Method of treating middle ear infections ➤ Sign Up
9,345,714 Method of treating middle ear infections ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 9,402,805

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Russian Federation 2295346 ➤ Sign Up
Russian Federation 2004111984 ➤ Sign Up
Poland 212457 ➤ Sign Up
Poland 369205 ➤ Sign Up
Mexico PA04002576 ➤ Sign Up
South Korea 20040035760 ➤ Sign Up
Japan 2005504804 ➤ Sign Up
Spain 2250739 ➤ Sign Up
European Patent Office 1429780 ➤ Sign Up CA 2012 00045 Denmark ➤ Sign Up
European Patent Office 1429780 ➤ Sign Up 13C0012 France ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Harvard Business School
Colorcon
UBS
Merck
US Department of Justice
Farmers Insurance
Mallinckrodt
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot